Генетическая карта здоровья (стр. 5 )

14. Emmerich, J., et al., Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost, 2001. 86(3): p. 809-16.

15. Renner, W., et al., Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res, 2000. 99(1): p. 35-9.

16. Gohil, R., G. Peck, and P. Sharma, The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls. Thromb Haemost, 2009. 102(2): p. 360-70.

17. Foka, Z. J., et al., Factor V leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod, 2000. 15(2): p. 458-62.

18. Abu-Skeen, I. A., et al., Factor V Leiden and prothrombin G20210A gene mutations in women with a history of thrombosis during pregnancy. Relation to pregnancy outcomes for mother and fetus. Saudi Med J, 2010. 31(2): p. 123-9.

19. Yenicesu, G. I., et al., A prospective case-control study analyzes 12 thrombophilic gene mutations in Turkish couples with recurrent pregnancy loss. Am J Reprod Immunol, 2009. 63(2): p. 126-36.

20. Goodman, C. S., et al., Which thrombophilic gene mutations are risk factors for recurrent pregnancy loss? Am J Reprod Immunol, 2006. 56(4): p. 230-6.

21. Juul, K., et al., Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. Ann Intern Med, 2004. 140(5): p. 330-7.

22. Eichinger, S., et al., Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med, 2008. 168(15): p. 1678-83.

23. Pomp, E. R., et al., Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost, 2008. 6(4): p. 632-7.

24. Chen, H. Y., et al., Estrogen receptor alpha polymorphism is associated with pelvic organ prolapse risk. Int Urogynecol J Pelvic Floor Dysfunct, 2008. 19(8): p. 1159-63.

25. Prandoni, P., The optimal duration of anticoagulant therapy in patients with venous thromboembolism, in Pathophysiology of haemostasis and thrombosis. Abstracts from the 21st International Congress on trombosis. Milan, Italy, July 6-9, 2010, P. M. Mannucci, Editor. 2010, Karger: Basel.

26. Jankun, J., et al., Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss. Int J Mol Med, 2010. 26(4): p. 501-4.

27. Mehta, R. and A. D. Shapiro, Plasminogen activator inhibitor type 1 deficiency. Haemophilia, 2008. 14(6): p. 1255-60.

28. Kuhli, C., et al., Massive subhyaloidal hemorrhage associated with severe PAI-1 deficiency. Graefes Arch Clin Exp Ophthalmol, 2005. 243(10): p. 963-6.

29. Agren, A., B. Wiman, and S. Schulman, Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity. Blood Coagul Fibrinolysis, 2007. 18(7): p. 657-60.

30. Panahloo, A., et al., Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes, 1995. 44(1): p. 37-42.

31. Simpson, A. J., et al., The effects of chronic smoking on the fibrinolytic potential of plasma and platelets. Br J Haematol, 1997. 97(1): p. 208-13.

32. Kruithof, E. K., Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins. Thromb Haemost, 2008. 100(6): p. 969-75.

33. Витковский, Ю. А., , and , Коллагенсвязывающая активность фактора Виллебранда, концентрация тканевого активатора плазминогена и его ингибитора у больных с механической травмой, in Общая реаниматология. 2009. p. 21-23.

34. Ma, Z., D. Paek, and C. K. Oh, Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clin Exp Allergy, 2009. 39(8): p. 1136-44.

35. Kohler, H. P. and P. J. Grant, Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med, 2000. 342(24): p. 1792-801.

36. Carmeliet, P., et al., Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation, 1997. 96(9): p. 3180-91.

37. Wiklund, P. G., et al., Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke, 2005. 36(8): p. 1661-5.

38. Naran, N. H., N. Chetty, and N. J. Crowther, The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity. Atherosclerosis, 2008. 196(1): p. 155-63.

39. Jeng, J. R., Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. Am J Hypertens, 2003. 16(4): p. 290-6.

40. Balta, G., C. Altay, and A. Gurgey, PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol, 2002. 71(2): p. 89-93.

41. Segui, R., et al., PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol, 2000. 111(1): p. 122-8.

42. Vergouwen, M. D., et al., Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke, 2004. 35(6): p. 1280-3.

43. Yamada, N., et al., The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet, 2000. 45(3): p. 138-41.

44. Cho, S. H., C. H. Ryu, and C. K. Oh, Plasminogen activator inhibitor-1 in the pathogenesis of asthma. Exp Biol Med (Maywood), 2004. 229(2): p. 138-46.

45. Buckova, D., L. Izakovicova Holla, and J. Vacha, Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy, 2002. 57(5): p. 446-8.

46. Kowal, K., et al., Analysis of -675 4G/5G SERPINE1 and C-159T CD14 polymorphisms in house dust mite-allergic asthma patients. J Investig Allergol Clin Immunol, 2008. 18(4): p. 284-92.

47. Cushman, M., The role of imflammation in Cardiovascular disease and effect of hormon replasment, in Материалы V международного симпозиума по проблемам здоровья женщин и менопаузе. 2004: Италия.

48. Макацария, А. Д., , and , Профилактика и лечение тромбоэмболических осложнений в акушерстве, in Тромбозы и тромбоэмболии в акушерско-гинекологической клинике. 2007, Медицинское информационное агенство: М. p. 1064.

49. Gerhardt, A., et al., The polymorphism of platelet membrane integrin alpha2beta1 (alpha2807TT) is associated with premature onset of fetal loss. Thromb Haemost, 2005. 93(1): p. 124-9.

50. Moshfegh, K., et al., Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet, 1999. 353(9150): p. 351-4.

51. Tsantes, A. E., et al., Lack of association between the platelet glycoprotein Ia C807T gene polymorphism and coronary artery disease: a meta-analysis. Int J Cardiol, 2007. 118(2): p. 189-96.

52. Nikolopoulos, G. K., et al., Integrin, alpha 2 gene C807T polymorphism and risk of ischemic stroke: a meta-analysis. Thromb Res, 2007. 119(4): p. 501-10.

, G., Z. Wang, and Y. Ding, Association of the platelet membrane glycoprotein I a C807T gene polymorphism with aspirin resistance. J Huazhong Univ Sci Technolog Med Sci, 2007. 27(6): p. 664-7.

54. Maeno, T., et al., The 807T allele in alpha2 integrin is protective against atherosclerotic arterial wall thickening and the occurrence of plaque in patients with type 2 diabetes. Diabetes, 2002. 51(5): p. 1523-8.

55. Yajnik, C. S., et al., Oral vitamin B12 supplementation reduces plasma total homocysteine concentration in women in India. Asia Pac J Clin Nutr, 2007. 16(1): p. 103-9.

56. van der Put, N. M., et al., Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet, 1995. 346(8982): p. 1070-1.

57. James, S. J., et al., Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr, 1999. 70(4): p. 495-501.

58. Mills, J. L., et al., Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. Am J Med Genet, 1999. 86(1): p. 71-4.

59. Skibola, C. F., et al., Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A, 1999. 96(22): p. 12810-5.

60. Lucock, M., Is folic acid the ultimate functional food component for disease prevention? BMJ, 2004. 328(7433): p. 211-4.

61. Penney, D. S. and K. G. Miller, Nutritional counseling for vegetarians during pregnancy and lactation. J Midwifery Womens Health, 2008. 53(1): p. 37-44.

62. Catania, J. and D. S. Fairweather, DNA methylation and cellular ageing. Mutat Res, 1991. 256(2-6): p. 283-93.

63. Vanyushin, B. F., et al., The 5-methylcytosine in DNA of rats. Tissue and age specificity and the changes induced by hydrocortisone and other agents. Gerontologia, 1973. 19(3): p. 138-52.

64. Costello, J. F. and C. Plass, Methylation matters. J Med Genet, 2001. 38(5): p. 285-303.

65. Matok, I., et al., Exposure To Folic Acid Antagonists During The First Trimester of Pregnancy and the Risk of Major Malformations. British Journal of Clinical Pharmacology, 2009. Early View, Date: September 2009.

66. Boccia, S., et al., Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. Cancer Lett, 2008.

67. Stidley, C. A., et al., Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res, 2010. 70(2): p. 568-74.

68. Silaste, M. L., et al., Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr, 2001. 131(10): p. 2643-7.

69. Laraqui, A., et al., Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease. Acta Cardiol, 2006. 61(1): p. 51-61.

70. Furness, D. L., et al., One-carbon metabolism enzyme polymorphisms and uteroplacental insufficiency. Am J Obstet Gynecol, 2008. 199(3): p. 276 e1-8.

71. Beetstra, S., et al., Methionine-dependence phenotype in the de novo pathway in BRCA1 and BRCA2 mutation carriers with and without breast cancer. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2565-71.

72. Barbosa, P. R., et al., Association between decreased vitamin levels and MTHFR, MTR and MTRR gene polymorphisms as determinants for elevated total homocysteine concentrations in pregnant women. Eur J Clin Nutr, 2008. 62(8): p. 1010-21.

73. Wilson, A., et al., A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Mol Genet Metab, 1999. 67(4): p. 317-23.

74. Zhu, H., et al., Homocysteine remethylation enzyme polymorphisms and increased risks for neural tube defects. Mol Genet Metab, 2003. 78(3): p. 216-21.